Colorectal cancer screening increased 12% and breast cancer screening increased 7% between 2019 and 2023. Cervical cancer screening remained 14% below rates from 2019, neither increasing or decreasing ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

Cervical cancer incidence is rising, with rural and minoritized populations experiencing worse outcomes due to suboptimal ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...